Current reports
6-K
Summary of Consolidated Financial Statements and Notes
21 Mar 24
6-K
Innate Pharma reports Full Year 2023 Financial Results and Business Update
21 Mar 24
6-K
Innate Pharma Announces Its Participation To Upcoming Investor Conference
19 Mar 24
6-K
Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results
14 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Innate Pharma Announces Its Participation To Upcoming Investor Conference
21 Feb 24
6-K
Current report (foreign)
6 Feb 24
6-K
Innate Pharma S.a. 6-K
12 Jan 24
6-K
Innate Pharma S.a. 6-K
5 Jan 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
6 Feb 24
F-3
Shelf registration (foreign)
20 Dec 23
424B5
Prospectus supplement for primary offering
26 Apr 23
424B5
Prospectus supplement for primary offering
3 May 22
S-8
Registration of securities for employees
12 Jul 21
F-3
Shelf registration (foreign)
13 Jan 21
424B4
Prospectus supplement with pricing info
18 Oct 19
FWP
Free writing prospectus
17 Oct 19
FWP
Free writing prospectus
17 Oct 19
POS EX
Additional exhibits for listing
16 Oct 19
Proxies
No filings
Other
EFFECT
Notice of effectiveness
17 Jan 24
CORRESP
Correspondence with SEC
11 Jan 24
UPLOAD
Letter from SEC
26 Dec 23
EFFECT
Notice of effectiveness
29 Jan 21
CORRESP
Correspondence with SEC
27 Jan 21
UPLOAD
Letter from SEC
19 Jan 21
EFFECT
Notice of effectiveness
22 Oct 19
EFFECT
Notice of effectiveness
17 Oct 19
CERT
Certification of approval for exchange listing
16 Oct 19
CORRESP
Correspondence with SEC
11 Oct 19